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ABSTRACT
Introduction: To investigate the factors that
affect the choice of 5-fluorouracil (5-FU) or its
oral alternative, capecitabine, as first-line
treatment in patients with colorectal cancer
(CRC).
Methods: Patients treated with 5-FU or
capecitabine for CRC between January 1, 2011
and December 31, 2013 in a teaching hospital
in the Sydney metropolitan area, Australia were
identified using the hospital’s database
MOSAIQ. The electronic medical record of
each patient was manually reviewed to extract
factors potentially affecting treatment choice.
Logistic regression was used to assess which
patient and/or treatment factors could explain
the choice between 5-FU or capecitabine. Where
it was available in the medical correspondence,
the explicit reason for the choice made was
extracted.
Results: 170 CRC patients were included; 119
on 5-FU, and 51 on capecitabine. The odds of
receiving capecitabine as a first-line treatment
were positively associated with giving patients
a choice in the decision (OR = 17.51, 95% CI:
5.37–57.08). Qualitative data suggest
treatment choices were motivated by
convenience (oral administration) and
tolerability. Time from diagnosis to
treatment commencement (OR = 1.02 per
month, 95% CI 1.00–1.04) was also found to
be positively associated with the choice of
capecitabine. The odds of being treated with
capecitabine were lower for patients who lived
further from the treating hospital (OR = 0.22,
95% CI 0.05–0.94).
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Conclusion: This study suggests that patient
choice, favoring oral capecitabine over i.v. 5-FU,
was a key factor influencing first-line treatment
for CRC in this cohort. To respect their
autonomy, patients should be involved in the
clinical decision making process.




Colorectal cancer (CRC) remains one of the
most common cancers worldwide. With an
estimated incidence of almost 1.4 million new
diagnoses, it represented 9.7% of all new cancer
diagnoses excluding non-melanoma skin
cancer. Worldwide, mortality has been
estimated to be nearly 694,000 [1]. To treat
CRC, a broad range of drugs is now available
including fluorouracil (5-FU) alone or with
leucovorin (LV), capecitabine, oxaliplatin,
irinotecan and targeted agents.
Fluoropyrimidines, 5-FU (intravenously
administered) and capecitabine (tablet
formulated prodrug of 5-FU), are generally
used as the backbone of treatment modalities,
either alone or in combination with other
agents [2, 3]. Numerous studies have
compared the efficacy and safety of 5-FU and
capecitabine, alone or in combination therapy.
Capecitabine, and the combination of
capecitabine and oxaliplatin (XELOX or
CAPOX) have been shown to be non-inferior
to either 5-FU/LV or the combination of 5-FU/
LV and oxaliplatin (FOLFOX or FLOX) [2, 4].
However, the decision to use one or the
other of these drugs has implications for both
the patient and treating institution; most
notably, for health care resource use due to
the difference in the mode of administration.
While intravenous (i.v.) treatment with 5-FU
typically requires the use of indwelling
catheters, pumps for continuous infusion and
several hospital visits by the patient or home
visits by medical personnel, capecitabine is
self-administered orally. Thus, the use of 5-FU
would be expected to result in increased health
care service utilization associated with
treatment administration compared with
capecitabine [5–12], as well as the costs to the
patient for traveling to, and remaining at the
hospital for treatment [6, 10, 11, 13]. Given
these differences in the mode of administration
and potential accessibility of treatment, several
studies have noted a preference by patients for
capecitabine over 5-FU on the basis of
convenience [14, 15].
Studies specifically evaluating patient
preferences for oral versus i.v. chemotherapy
(mostly for CRC) generally show a preference
for oral treatment [14–19]. Before and after
treatment, the main drivers of preference for
oral chemotherapy were convenience of home
administration [14–18], the avoidance of i.v.
line problems [16, 18], fewer adverse events
(AEs) [17, 18] and oral administration [14, 15,
17]. Interestingly, Twelves et al. [14] found
fewer occurrences of AEs to be a driver of
preference for 5-FU. Other studies have shown
that home-based chemotherapy treatments
were preferred by the patients [20, 21] and led
to significant [21] or greater treatment
satisfaction [22]. The reasons associated with
this preference were convenience, traveling less,
lower anxiety, not having to trouble carers and
family, having a greater ability to perform other
tasks and having a relative close-by [20, 21].
The aim of this study was to identify the
factors associated with the choice between 5-FU
and capecitabine in the first-line treatment of
patients with CRC using data from the
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electronic medical records of an Australian
metropolitan public hospital. Previous studies
have identified factors such as patient age,
comorbidities, gender, race, median income,
marital status, type of insurance, area of
residence, and cancer specific characteristics
such as CRC stage, cancer site, prior cancer
events, and year of diagnosis as influencing
prescribing decisions [23–31]. We sought to
consider these factors against the role of
patient choice and their actual involvement in
treatment decision making where documented.
A secondary aim was to specifically identify
patients’ underlying reasons for their treatment
choice where this information was available.
METHODS
Setting and Study Population
This was a retrospective, single center study
conducted at a teaching hospital in the Sydney
metropolitan area. The records of CRC patients
who received active treatment via that hospital
with 5-FU or capecitabine between January 1,
2011 and December 31, 2013 were included.
Eligible patients were identified using a
proprietary database, MOSAIQ, the primary
electronic database used for outpatient
oncology records at the hospital since 2011. If
a diagnosis or treatment was unclear, a medical
oncologist (MC) and a pharmacist (BL) were
consulted to decide whether or not to include
that patient in the analysis. For all included
patients the choice of first-line treatment, i.v.
5-FU or oral capecitabine was assessed. Patients
who started first-line treatment before January
1, 2011 but were treated during the study period
were included in the analysis.
Potential Factors Affecting Treatment
Choice
Potential factors affecting the decision to use
either 5-FU or capecitabine as the first-line
treatment were identified by a comprehensive
literature review [14–31] and supplemented by
additional factors hypothesized to also impact
on the treatment decision. In addition to
patient preference as described above, patient
demographics and clinical characteristics may
also influence treatment choice. Patient and
disease characteristics shown to be associated
with chemotherapy treatment choice explored
in this study were: age, comorbidity, sex,
ethnicity (proxied by birthplace), income,
marital status, type of insurance, geographic
region, CRC stage, cancer site, prior cancer
events, and year of diagnosis [23–31].
Additional factors included in this study were
number of children, religious affiliation, time
from diagnosis to treatment commencement,
initial attending physician, involvement of
radiation oncologist and prescribing medical
oncologist. These factors were included given
their availability and speculation of their
potential influence on treatment choice. In
Australia, 5-FU and capecitabine are subsidized
by the Pharmaceutical Benefits Scheme for
treatment of CRC resulting in no real financial
cost differences for patients. Drug acquisition
costs were therefore excluded as a factor
influencing choice.
Data were manually extracted from the
standard demographic, medical and prescription
records within the MOSAIQ database. Where
additional information was required that was
not contained in MOSAIQ, patient-specific
medical oncology correspondence was reviewed.
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For all patients this included searching for
information on a number of variables (number
of children, comorbidities, stage of CRC at
treatment commencement, treatment decision
and prescribing medical oncologist) and for
qualitative information on the underlying
reasons regarding treatment preference from
medical correspondence. This included
correspondence between medical practitioners
and entries in patient medical notes, not
specifically addressed to a third party. For some
patients, data had to be extracted from older
databases used before MOSAIQ. Data not
available in any database including the medical
correspondence were recorded as ‘‘not reported’’.
All data were extracted on site by one author (LB).
To verify the validity of the extraction process, a
medical oncologist (MC) who had experience
using MOSAIQ, double-checked the extracted
variables for a sample of patients.
Text extracted from the medical oncology
correspondence on the reason for choosing the
first-line chemotherapy regimen was initially
coded by one researcher (LB). Treatment
decisions were categorized into how and by
whom they were made (e.g., by the patient, by
the physician, or unclear, see Table 1), with
supplementary information as to why a
decision was made (e.g., convenience,
tolerability), extracted based on key-words
appearing in the medical record text. Coding
decisions were then discussed with another
researcher (RL) to ensure consistent
classification.
Data Analysis
Factors affecting the decision to use either 5-FU
or capecitabine were analyzed using logistic
regression. The treatment decision was the
dependent variable, coded as binary between
capecitabine and 5-FU. With the exception of
age, time from diagnosis to treatment and
distance required to travel to hospital,
variables extracted from MOSAIQ and the
supporting medical correspondence were
coded as categorical.
Initial associations between categorical
variables and treatment choice were examined
using univariate two-way tabulations and tested
for statistical significance using Pearson’s
Chi-squared test and Crame´rs V. For those
variables where the tests indicated a possible
significant association (p value\0.1 for
Chi-squared test, or Crame´rs V[0.2) an odds
ratio (OR) was tabulated and tested for
homogeneity. All variables which showed
either a significantly increased OR, or which
Table 1 Treatment decision categories
Category Medical oncology correspondence
clearly indicated that…
Physician …the physician had decided which




…one option was discussed with the
patient by the physician
Physician
recommended
…a speciﬁc treatment regimen was
advised/recommended to the patient
by the physician, but ﬁnal choice was
left to the patient
Patient …the patient had decided to use a
speciﬁc treatment; generally after
multiple optional treatment regimens
were offered
Ambiguous None of the above could be inferred
from the note, thus leaving it unclear
how the treatment decision had been
made
Not reported N/A, a letter was not available, or there
was no information in the patient
correspondence on the treatment
decision
N/A not applicable
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tested positive for homogeneity were retained
for inclusion in the multivariate logistic
regression. Despite not demonstrating
significance, gender was retained for inclusion
as a known demographic of influence, but all
the other categorical variables that did not show
a significant univariate association were
excluded from the multivariate logistic
regression.
The subsequent multivariate logistic
regression included the categorical variables of
significance, gender and the continuous
variables of age, time from diagnosis to
treatment and distance from the treating
institution. The latter variable was
subsequently converted to categorical to better
capture the distribution of patients and to
overcome the impact of extreme data-points
on the modeled analysis. Missing data were
excluded for all variables. Data analyses were
undertaken using Microsoft Excel 2010 and
Stata Statistical Software, release 13.
Compliance with Ethics Guidelines
This article is based on previously treated
patients and does not involve any new
studies of human or animal subjects
performed by any of the authors. Ethics
approval for this study was obtained from the
South Eastern Sydney Local Health District
Human Research Ethics Committee (13/288)
and ratified by the University of Technology




Review of the MOSAIQ database revealed that a
total of 170 CRC patients were eligible for
inclusion in this analysis; 119 patients had
received initial treatment with 5-FU (14 as
single agent), while 51 commenced treatment
with a capecitabine-based regimen (22 as single
agent). Patient, disease and treatment
characteristics are presented in Table 2. 61.8%
of patients were male and the average age at
treatment commencement was 63.3 years. 100
patients (58.8%) were initially diagnosed with a
form of colon cancer, of which more than a
third had cancer of the sigmoid colon, while the
other 70 patients had rectal cancer. The average
time between diagnosis and treatment
commencement was 7.63 months, with a very
wide range (SD = 19.52 months). The available
data indicate that in only 41 (24.1%) instances
was the patient clearly given a choice between
starting therapy with either 5-FU or
capecitabine. Of the six treating physicians
responsible for all 170 patients, one medical
oncologist treated almost 70% of the patients,
with two others treating more than 10% of the
patients. A similar distribution of patients was
observed for the initial attending physician and
the radiation oncologist involved.
Factors Influencing Treatment Choice
Variation
Two-way tabulation of the categorical variables
with the dependent variable yielded significant
Chi-squared values for ‘‘marital status’’ and
‘‘treatment decision’’ and near significant
results for ‘‘religious affiliation’’ and ‘‘radiation
oncologist’’. The cut-off for Crame´rs V was
reached for all four variables. The full results
of the two-way tabulations for the categorical
variables can be found online. Homogeneity
testing and calculation of OR was performed for
these four variables. Significantly increased
univariate OR were found for ‘‘religious
affiliation’’, ‘‘marital status’’ and ‘‘treatment
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Table 2 Patient, disease and treatment characteristics of


















Not speciﬁed/unknown 3 (1.8%)




Not reported 48 (28.2%)
Religious afﬁliation
Religious 88 (51.8%)
Not religious 28 (16.5%)
Not speciﬁed/unknown/not reported 54 (31.8%)
Health insurance
Only public health insurance 110 (64.7%)
At least public health insuranceb 14 (8.2%)
No private health insurance 14 (8.2%)
Public and private health insurance 8 (4.7%)
Private health insurance 5 (2.9%)
Not known/not otherwise stated 2 (1.2%)
Table 2 continued
Characteristic N (%)a






Not reported 19 (11.2%)





Average (km [st.dev]) 38.71 [114.72]






C18.0 (caecum) 19 (11.2%)
C18.2 (ascending colon) 15 (8.8%)
C18.3 (hepatic ﬂexure) 2 (1.2%)
C18.4 (transverse colon) 5 (2.9%)
C18.5 (splenic ﬂexure) 3 (1.8%)
C18.6 (descending colon) 7 (4.1%)
C18.7 (sigmoid colon) 36 (21.2%)
C18.8 (overlapping sites of colon) 0 (0.0%)
C18.9 (colon, unspeciﬁed) 1 (0.6%)
C19 (rectosigmoid junction) 12 (7.1%)
C20 (rectum) 70 (41.2%)
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decision’’ with significant homogeneity test
results for the latter two variables.
The results of the logistic regression are
presented in Table 3. Significant results were
observed for three variables: patients being
given the choice for the treatment decision;
time from diagnosis to treatment; and distance
from the treating center. First, documentation
by the physician that the patient was given a
choice of treatment was associated with a
higher odds of using capecitabine compared
to 5-FU (OR = 17.51, 95% CI 5.37–57.08).
Second, the length of time between diagnosis
and commencement of treatment was also
significant; the odds of using capecitabine,
relative to 5-FU, increased the longer was this
interval (OR = 1.02 per month, 95% CI
1.00–1.04). Finally, the distance from the
patient’s home to the hospital was also a
predictor of treatment choice; patients living
more than 40 km from the treating center were
less likely to be treated with capecitabine
(OR = 0.22, 95% CI 0.05–0.94). The
remaining variables did not statistically
significantly influence the odds of
commencing treatment with capecitabine
when compared with 5-FU.
Reasons for Treatment Preference
While it was possible to categorize all the
patients according to who made the
treatment decision, there was little
information available on the underlying
reasons for this preference. Such information
was present in the clinical letters of only 11
patients; of these, two were treated with 5-FU
and nine with capecitabine. The underlying
reasons, by treatment, are listed in Table 4.
Convenience seemed to be the main reason for
a preference for capecitabine, associated with
its oral mode of administration, and reduced
time spent traveling to or visiting the hospital.
However, a difference in adverse event profiles
also seemed to play a role in a preference for
capecitabine. Reasons supporting the choice of
5-FU over capecitabine were stated for two
patients: potential adverse events with









No tumor 1 (0.6%)
Unknown 1 (0.6%)










One option discussed 37 (21.8%)
Physician recommended 18 (10.6%)
Patient 41 (24.1%)
Ambiguous 17 (10.0%)
Not reported 11 (6.5%)
SD standard deviation
a Numbers represent the number of patients, unless
otherwise speciﬁed
b Equals ‘public’ (insurance) in the medical record, while
for publicly but non-privately insured this was explicitly
noted as ‘public, not private’
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DISCUSSION
The results from our study indicate that three
variables were significant in explaining the
variation in 5-FU and capecitabine use in the
first-line treatment of the identified CRC
patient cohort: giving the patient a choice of
treatment and a longer time between diagnosis
and treatment commencement were
significantly associated with choosing





Odds ratioa 95 % conﬁdence
interval
Gender
Female 21 (35%) 39 (65%) Ref. – –
Male 27 (28%) 70 (72%) 1.10 0.45 2.69
Age
Age at treatment commencement
(per year)
66.95 62.55 1.02 0.98 1.07
Marital status
Married 20 (26%) 57 (74%) Ref. – –
Widowed, divorced/separated,
never married
19 (32%) 40 (68%) 1.67 0.62 4.45
Religious afﬁliation
Religious 23 (28%) 59 (72%) Ref. – –
Not religious 5 (19%) 21 (81%) 0.42 0.10 1.77
Distance required to travel to hospital (km)
0–5 25 (33%) 50 (67%) Ref. – –
5–10 15 (30%) 35 (70%) 0.74 0.27 2.02
10–40 6 (32%) 13 (68%) 1.47 0.39 5.47
[40 2 (15%) 11 (85%) 0.22 0.05 0.94
Treatment delay
Time from diagnosis to treatment
(per month)
10.04 7.18 1.02 1.00 1.04
Treatment decision
Physician 7 (15%) 39 (85%) Ref. – –
One option discussed 6 (16%) 31 (84%) 1.41 0.38 5.20
Physician recommended 4 (22%) 14 (78%) 1.41 0.29 6.86
Patient 27 (68%) 13 (33%) 17.51 5.37 57.08
Ambiguous 4 (25%) 12 (75%) 2.40 0.47 12.31
a Odds ratios adjusted for all variables in the logistic regression
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capecitabine, while patients living some
distance from the hospital were less likely to
be treated with capecitabine. The latter seems
paradoxical at first, as it might be expected that
patients living further from the hospital would
prefer, or be offered, oral treatments such as
capecitabine to enable them to stay at home
whilst on treatment and avoid regular hospital
visits. It is possible that patients made a choice
to sacrifice time away from home to complete
each cycle of treatment in hospital (resulting in
an overall shorter time on treatment; 48 h of
treatment on 5-FU or FOLFOX chemotherapy vs
2 weeks on capecitabine or CAPOX), or a
perception by the physician of differences in
the type of toxicity that might be encountered
and the capacity to deal with those toxicities
remotely. While toxicity data were not
available, the impact of potential
comborbidities was tested in univariate
analyses and found to not influence choice. In
addition, the influence of contraindications on
treatment choice was noted where these were
specifically stated in patient notes.
Table 4 Underlying reasons for preference regarding a speciﬁc treatment decision
Reasons to choose 5-FU Treatment decision
category
‘‘Given the potential for hand-foot syndrome with capecitabine,
it is likely that she will prefer intravenous 5-FU’’
Patient
‘‘… she had an asymptomatic pulmonary embolus requiring anti-coagulation. (…)
this precluded her from participating in the trial that would access oral capecitabine’’
Physician
Reasons to choose capecitabine Treatment decision
category
‘‘… he preferred not to have a portacath’’ Patient
‘‘She is not keen to have intravenous treatment’’ Patient
‘‘He was not keen to have infusional chemotherapy in the beginning and his difﬁculty
with mobility and discomfort with long waits has further convinced him so’’
Patient
‘‘… there is ample data to suggest it is equivalent and possibly better tolerated and
certainly far less cumbersome for the patient leading to other cost savings in terms of
time spent in chemotherapy administration’’
One option discussed
‘‘… he is not very keen (…) as he does not want to take time off work to allow for the
2 days that he will need to attend every fortnight’’
Patient
‘‘We have advised that he receive oral capecitabine, concurrent with the radiotherapy, as
this tends to be better tolerated than intravenous 5-ﬂuorouracil (5-FU)’’
Physician recommended
‘‘I thought it was reasonable to offer her palliative systemic chemotherapy but, in an
attempt to reduce the risk of signiﬁcant toxicity, I thought it appropriate to start with
single agent oral 5-ﬂuorouracil analogue capecitabine’’
Physician
‘‘In view of the equal efﬁcacy of both the agents the patient would prefer, from a
convenience point of view, to have treatment with capecitabine’’
Patient
‘‘… given the fact that she already has metastasis, she is eligible for the oral version of
analogue of 5-ﬂuorouracil capecitabine’’
Physician
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Our results show that the time from diagnosis
to commencement of treatment was
significantly associated with choosing
capecitabine. While it is possible that the
increased time interval between diagnosis and
commencement of treatment, which was noted
to be significant, was a surrogate marker for
performance status or increased co-morbidities,
it would be speculative to state that this was the
case for all patients. Unfortunately ECOG
performance was not available for patients in
this sample: performance status was not always
sequentially recorded in the electronic health
record, MOSAIQ. The number of comorbidities
was available, but initial univariate testing
showed no association between the number of
comorbidities and treatment choice so this was
excluded from subsequent multivariate analyses.
A caveat to this result is that the records used
to inform our analysis did not consistently
capture the time of disease recurrence where it
occurred, such that the actual interval between
newly emergent disease requiring treatment
and treatment starting may be shorter than
calculated. This could not be clarified further
with the available data. Data issues
notwithstanding, we found it difficult to
explain that the longer a treatment decision
appeared to be deferred, the higher was the
chance that a patient was treated with a
capecitabine-based regimen. We explored the
possibility that the timing of public subsidy for
capecitabine played a part, given that it was not
recommended for funding until November
2008 for metastatic CRC in conjunction with
oxaliplatin (CAPOX), sometime after the
availability of publicly subsidized 5-FU. A
supplementary regression including a dummy
variable for the introduction of subsidized
capecitabine failed to show significance in this
regard. Perhaps it could indicate a more
considered and resolute decision by the
patient. That is, this variable might be a proxy
for expected tolerability effects associated with
5-FU; that is, the further patients are away from
their initial diagnosis the less likely they are to
accept what might be considered ‘‘invasive’’
treatments and perhaps use capecitabine as a
single agent in this category.
The main factor influencing treatment
choice was a treatment decision made by the
patient compared with one made by the
physician. When patients were given a choice,
the chances that a treatment decision was made
in favor of capecitabine rather than 5-FU were
significantly higher. This finding corresponds to
previously reported studies of patient
preference: provided that efficacy is not
compromised, most patients expressed a
preference for oral chemotherapy compared to
i.v. treatment, mostly due to the convenience of
oral administration at home, the avoidance of
i.v. line problems and fewer AEs [14–22]. Our
review of patients’ clinical records revealed
similar underlying reasons for patient
preferences: the convenience of oral
administration, and less travel and waiting
time. Care is required when drawing
conclusions based on this outcome, as the
extracted sections of medical correspondence
that described the treatment decision process
were highly variable in terms of the amount of
text and detail provided and were only available
for a small number of patients. Treatment
intent was not extracted from the database so
it would be speculative to comment on this
point beyond what could be extracted from the
patient notes. However, active involvement of
patients in the treatment decision process is a
recommended aspect of patient-centered care as
it indicates respect for their autonomy.
Indeed, patient participation in the medical
decision making process has been shown to
influence patient satisfaction [32]. Women with
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breast cancer who were not given the
opportunity to make a choice fared less well
psychologically (they expressed a diminished
positive attitude) than women who were offered
a choice between treatment options. In
addition, final decision making by the patient
rather than the physician led to greater
psychological wellbeing [32]. Other studies
have shown that a majority of patients prefer
to make either an autonomous or a shared
decision (i.e., together with their physician) [16,
33, 34]. In a recent review of patient preferences
related to the choice of treatment and mode of
decision making, Damm et al. [35] found that
the majority of CRC patients expressed a
preference for a passive role in the decision
making process . This is consistent with our data
in which approximately 60% of decisions were
the result of a direct choice by the physician, or
indicate some degree of physician direction.
Nonetheless, our results suggest that patient
involvement in treatment choice is a significant
predictor of the use of capecitabine compared
with 5-FU. It might be reasonable to expect
therefore that if more patients were able to be
actively involved in treatment decision making,
the use of capecitabine might be higher than we
have observed.
There are several limitations to this study.
First, it was conducted at one site in Australia,
and almost 70% of patients were treated by
one physician. This limits the external
applicability of our results, both within the
Australian setting and to other jurisdictions
where differences in clinical practice or access
to chemotherapy might impact on the choice
of treatment for CRC. Second, the information
extracted from medical correspondence was
variable and relied on what had been entered.
This varied, in terms of both consistency and
detail. As a result, for instance, it was not
feasible to determine if a shared decision
making approach was actually used, only to
dichotomise how decisions were made.
Physician attitudes and biases toward one
treatment or another have not been fully
explored. Finally, our study had a limited
number of observations: 170 cases of CRC
that were not evenly balanced across the
treatment groups were extracted from the
relevant database. This, coupled with the
existence of a substantial proportion of
missing data for a number of variables,
reduces the explanatory power of our
analysis. With larger study populations, more
significant associations might have been
discovered, including between the different
options of treatment: single agent vs
combinations. Two other studies that also
examined treatment patterns for capecitabine
and 5-FU included 4250 and 636 patients
respectively [36, 37]. Both assessed factors
associated with treatment choices for single
agent as well as combination therapy (CAPOX/
XELOX vs. FOLFOX) as first-line treatment in
(metastatic) CRC patients from the USA and
Australia. In the study by Satram-Hoang et al.
[36], the population who received capecitabine
rather than 5-FU was older, and a higher
proportion was female, had lower CRC stage
at diagnosis but a higher tumor grade, and had
higher incomes. Comorbidity score and race
were not associated with a specific single agent
treatment. CAPOX treatment was associated
with a higher overall CRC stage at diagnosis
and a trend was observed toward people in this
group being older. Comorbidity, sex, race,
income and tumor grade were not associated
with a specific multi-agent therapy. Compared
to those receiving i.v. treatment, more patients
receiving capecitabine or CAPOX were living in
western USA, and a higher proportion had at
least a college degree [36]. Finally, in Australia,
patient age at diagnosis was found to be
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significant, with older patients more often
receiving single agent capecitabine, as well as
primary tumor site, with colon cancer patients
more often receiving FOLFOX [37].
Notably, these studies focused only on
patient and disease characteristics as
determinants of treatment modality and not
the source of the treatment decision. It is likely
that in making their treatment choice, patients
and physicians alike evaluate some of the
disease and patient characteristics considered
in those larger studies. However, using the
information available in patients’ charts, we
were able to identify that convenience is an
additional underlying reason which influences
preferences.
CONCLUSION
In conclusion, the striking difference in the
choice of treatment between patients who made
the decision concerning choice of treatment
and those for whom physicians chose
demonstrates the importance of patient
preferences in decision making. Actively
involving patients in the decision making
process, demonstrates respect for their
autonomy, an important aspect of
patient-centered care.
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